2-[(3-ethylphenoxy)methyl]oxirane | 2210-81-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[(3-ethylphenoxy)methyl]oxirane
• CAS: 2210-81-3
• 化学式: C₁₁H₁₄O₂
• mdl: MFCD06655044
• 分子量: 178.231
• InChiKey: FXRJOSAKLOBJFS-UHFFFAOYSA-N

物化性质

• 沸点：
  273.5±13.0 °C(Predicted)
• 密度：
  1.070±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(5-phenyl-thieno[2,3-d]pyrimidine-4-yl)-piperidin-4-ylamine 、 2-[(3-ethylphenoxy)methyl]oxirane 以 异丙醇 为溶剂， 生成 C₂₈H₃₂N₄O₂S
  参考文献：
  名称：

  Thienopyrimidines as β3-adrenoceptor agonists: Hit-to-lead optimization

  摘要：

  Resulting from a vHTS based on a pharmacophore alignment on known beta 3-adrenoceptor ligands, an aryloxypropanolamine scaffold comprising a thienopyrimidine moiety was further optimized as a human beta 3-AR agonist, yielding a lead compound with an excellent cellular activity of EC(50) = 20 pM, selectivity over h beta 1- and h beta 2- adrenoceptors and a promising safety profile. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.039
• 作为产物：
  描述：

  3-乙基苯酚 、 环氧溴丙烷 在 potassium carbonate 作用下， 以 丁酮 为溶剂， 反应 69.3h， 以100%的产率得到2-[(3-ethylphenoxy)methyl]oxirane
  参考文献：
  名称：

  AROMATIC GLYCOL ETHERS AS WRITING MONOMERS IN HOLOGRAPHIC PHOTOPOLYMER FORMULATIONS

  摘要：

  本发明涉及一种光聚合配方，包含特定的芳香族乙二醇醚作为写入单体、基质聚合物和光引发剂。本发明还提供了一种使用创新光聚合配方可获得的未曝光全息介质，以及通过将全息图曝光到创新的未曝光全息介质中获得的曝光全息介质。本发明同样提供了一种包含创新曝光全息介质的视觉显示，用于创新曝光全息介质在生产芯片卡、身份证件、三维图像、产品保护标签、标签、钞票或全息光学元件中的应用，以及特定的芳香族乙二醇醚。

  公开号：

  US20170045816A1

文献信息

• New functionalization of graphene oxide with N ₂ O ₂ ligand for efficient loading of Cu nanostructures as a heterogeneous nanocatalyst for the synthesis of β‐hydroxy‐1,2,3‐triazoles
  作者：Mansoureh Rakhshanipour、Hossein Eshghi、Mehdi Bakavoli

  DOI：10.1002/aoc.5426

  日期：2020.3

  nanocatalyst was analyzed using various techniques. Most of the analyses confirmed the successful anchoring of copper and organic ligand on the GO surface. Moreover, the synthesized nanocatalyst has shown high catalytic activity in the synthesis of β‐hydroxy‐1,2,3‐triazole derivatives under mild reaction conditions (water and room temperature) resulting in good to excellent yields.

  制备了固定在氧化石墨烯（GO）上的新型异质铜配合物。这是通过使用1,8-二氨基-3,6-二氧杂辛烷（DADO）对GO进行有机官能化，然后在官能化的GO（GO-DADO-Cu）的边缘和基面上对铜进行无机配位而减少的至Cu（0）。使用各种技术分析了制备的纳米催化剂的化学结构。大多数分析证实了铜和有机配体在GO表面的成功锚固。此外，在温和的反应条件（水和室温）下，合成的纳米催化剂在合成β-羟基1,2,3-三唑的过程中显示出很高的催化活性，从而产生了很好的产率。
• Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use Thereof
  申请人：Paris Daniel

  公开号：US20080058330A1

  公开（公告）日：2008-03-06

  Provided are compounds which can be used in combination for treating diseases associated with a condition associated with cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which in combination can decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of the compounds.

  提供了一些化合物，可以组合使用来治疗与阿尔茨海默病淀粉样蛋白相关的疾病，如阿尔茨海默病。还提供了一种方法，通过给予治疗有效量的化合物组合来减少β-淀粉样蛋白的产生和细胞中的电容性钙离子进入，从而治疗或降低发生β-淀粉样蛋白产生、β-淀粉样蛋白沉积、β-淀粉样蛋白神经毒性（包括tau异常过度磷酸化）和与阿尔茨海默病淀粉样蛋白相关的微胶质病变。此外，还提供了一种方法，通过给予诊断有效量的化合物来诊断动物或人类中与阿尔茨海默病淀粉样蛋白相关的疾病。
• Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
  申请人：Mullan J. Michael

  公开号：US20070037855A1

  公开（公告）日：2007-02-15

  Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells.

  提供的化合物可用于治疗与阿尔茨海默淀粉样蛋白在大脑中积累有关的疾病，例如阿尔茨海默病。还提供了筛选此类化合物的方法，通过测量细胞中的电容性钙离子进入，其中细胞可以选择性地过度表达APP或其片段。还提供了通过给予治疗有效量的化合物来治疗或降低β-淀粉样蛋白产生、β-淀粉样蛋白沉积、β-淀粉样蛋白神经毒性（包括tau的异常高磷酸化）和与阿尔茨海默淀粉样蛋白在大脑中积累有关的微胶质细胞增生的方法。此外，还提供了通过给动物或人类施用诊断有效量的抑制电容性钙离子进入细胞的化合物来诊断与阿尔茨海默淀粉样蛋白在大脑中积累有关的疾病的方法。
• Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives
  申请人：Kim Bum Tae

  公开号：US20080280901A1

  公开（公告）日：2008-11-13

  The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.

  本发明涉及使用特定的α-芳基甲氧基丙烯酸酯衍生物或其药理学上可接受的盐或溶剂来预防和治疗代谢性骨疾病。
• Compounds for Inhibiting Beta-Amyloid Production and Methods of Identifying the Compounds
  申请人：Mullan Michael J.

  公开号：US20100215735A1

  公开（公告）日：2010-08-26

  Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells.

  提供了一些化合物，可用于治疗与阿尔茨海默氏淀粉样物质在大脑中积累有关的疾病，如阿尔茨海默病。还提供了筛选这些化合物的方法，通过测量在细胞中的电容性钙离子进入，这些细胞可以选择性地过表达APP或其片段。还提供了通过给予治疗有效量的化合物来治疗或降低发生β-淀粉样物质产生、β-淀粉样物质沉积、β-淀粉样物质神经毒性（包括tau异常过磷酸化）和与阿尔茨海默氏淀粉样物质在大脑中积累有关的小胶质细胞增生的风险的方法，这些化合物可以减少β-淀粉样物质产生和细胞中的电容性钙离子进入。此外，还提供了通过给动物或人体内给予诊断有效量的化合物来诊断与阿尔茨海默氏淀粉样物质在大脑中积累有关的疾病的方法，这些化合物可以抑制细胞中的电容性钙离子进入。